Cargando…

Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1

Autosomal-dominant spinocerebellar ataxias (SCA) are neurodegenerative diseases characterized by progressive ataxia. Here, we report on neurometabolic alterations in spinocerebellar ataxia type 1 (SCA1; SCA-ATXN1) and 14 (SCA14; SCA-PRKCG) assessed by non-invasive (1)H magnetic resonance spectroscop...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosch, Anne Sophie, Rinnenthal, Jan Leo, Rönnefarth, Maria, Lux, Silke, Scheel, Michael, Endres, Matthias, Brandt, Alexander U., Paul, Friedemann, Schmitz-Hübsch, Tanja, Minnerop, Martina, Doss, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004522/
https://www.ncbi.nlm.nih.gov/pubmed/33063293
http://dx.doi.org/10.1007/s12311-020-01201-y
_version_ 1783671926833545216
author Grosch, Anne Sophie
Rinnenthal, Jan Leo
Rönnefarth, Maria
Lux, Silke
Scheel, Michael
Endres, Matthias
Brandt, Alexander U.
Paul, Friedemann
Schmitz-Hübsch, Tanja
Minnerop, Martina
Doss, Sarah
author_facet Grosch, Anne Sophie
Rinnenthal, Jan Leo
Rönnefarth, Maria
Lux, Silke
Scheel, Michael
Endres, Matthias
Brandt, Alexander U.
Paul, Friedemann
Schmitz-Hübsch, Tanja
Minnerop, Martina
Doss, Sarah
author_sort Grosch, Anne Sophie
collection PubMed
description Autosomal-dominant spinocerebellar ataxias (SCA) are neurodegenerative diseases characterized by progressive ataxia. Here, we report on neurometabolic alterations in spinocerebellar ataxia type 1 (SCA1; SCA-ATXN1) and 14 (SCA14; SCA-PRKCG) assessed by non-invasive (1)H magnetic resonance spectroscopy. Three Tesla (1)H magnetic resonance spectroscopy was performed in 17 SCA14, 14 SCA1 patients, and in 31 healthy volunteers. We assessed metabolites in the cerebellar vermis, right cerebellar hemisphere, pons, prefrontal, and motor cortex. Additionally, clinical characteristics were obtained for each patient to correlate them with metabolites. In SCA14, metabolic changes were restricted to the cerebellar vermis compared with widespread neurochemical alterations in SCA1. In SCA14, total N-acetylaspartate (tNAA) was reduced in the vermis by 34%. In SCA1, tNAA was reduced in the vermis (24%), cerebellar hemisphere (26%), and pons (25%). SCA14 patients showed 24% lower glutamate+glutamine (Glx) and 46% lower γ-aminobutyric acid (GABA) in the vermis, while SCA1 patients showed no alterations in Glx and GABA. SCA1 revealed a decrease of aspartate (Asp) in the vermis (62%) and an elevation in the prefrontal cortex (130%) as well as an elevation of myo-inositol (Ins) in the cerebellar hemisphere (51%) and pons (46%). No changes of Asp and Ins were detected in SCA14. Beyond, glucose (Glc) was increased in the vermis of both SCA14 (155%) and SCA1 (247%). (1)H magnetic resonance spectroscopy revealed differing neurochemical profiles in SCA1 and SCA14 and confirmed metabolic changes that may be indicative for neuronal loss and dysfunctional energy metabolism. Therefore, (1)H magnetic resonance spectroscopy represents a helpful tool for in-vivo tracking of disease-specific pathophysiology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12311-020-01201-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8004522
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-80045222021-04-16 Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1 Grosch, Anne Sophie Rinnenthal, Jan Leo Rönnefarth, Maria Lux, Silke Scheel, Michael Endres, Matthias Brandt, Alexander U. Paul, Friedemann Schmitz-Hübsch, Tanja Minnerop, Martina Doss, Sarah Cerebellum Original Article Autosomal-dominant spinocerebellar ataxias (SCA) are neurodegenerative diseases characterized by progressive ataxia. Here, we report on neurometabolic alterations in spinocerebellar ataxia type 1 (SCA1; SCA-ATXN1) and 14 (SCA14; SCA-PRKCG) assessed by non-invasive (1)H magnetic resonance spectroscopy. Three Tesla (1)H magnetic resonance spectroscopy was performed in 17 SCA14, 14 SCA1 patients, and in 31 healthy volunteers. We assessed metabolites in the cerebellar vermis, right cerebellar hemisphere, pons, prefrontal, and motor cortex. Additionally, clinical characteristics were obtained for each patient to correlate them with metabolites. In SCA14, metabolic changes were restricted to the cerebellar vermis compared with widespread neurochemical alterations in SCA1. In SCA14, total N-acetylaspartate (tNAA) was reduced in the vermis by 34%. In SCA1, tNAA was reduced in the vermis (24%), cerebellar hemisphere (26%), and pons (25%). SCA14 patients showed 24% lower glutamate+glutamine (Glx) and 46% lower γ-aminobutyric acid (GABA) in the vermis, while SCA1 patients showed no alterations in Glx and GABA. SCA1 revealed a decrease of aspartate (Asp) in the vermis (62%) and an elevation in the prefrontal cortex (130%) as well as an elevation of myo-inositol (Ins) in the cerebellar hemisphere (51%) and pons (46%). No changes of Asp and Ins were detected in SCA14. Beyond, glucose (Glc) was increased in the vermis of both SCA14 (155%) and SCA1 (247%). (1)H magnetic resonance spectroscopy revealed differing neurochemical profiles in SCA1 and SCA14 and confirmed metabolic changes that may be indicative for neuronal loss and dysfunctional energy metabolism. Therefore, (1)H magnetic resonance spectroscopy represents a helpful tool for in-vivo tracking of disease-specific pathophysiology. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12311-020-01201-y) contains supplementary material, which is available to authorized users. Springer US 2020-10-15 2021 /pmc/articles/PMC8004522/ /pubmed/33063293 http://dx.doi.org/10.1007/s12311-020-01201-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Grosch, Anne Sophie
Rinnenthal, Jan Leo
Rönnefarth, Maria
Lux, Silke
Scheel, Michael
Endres, Matthias
Brandt, Alexander U.
Paul, Friedemann
Schmitz-Hübsch, Tanja
Minnerop, Martina
Doss, Sarah
Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title_full Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title_fullStr Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title_full_unstemmed Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title_short Neurochemical Differences in Spinocerebellar Ataxia Type 14 and 1
title_sort neurochemical differences in spinocerebellar ataxia type 14 and 1
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004522/
https://www.ncbi.nlm.nih.gov/pubmed/33063293
http://dx.doi.org/10.1007/s12311-020-01201-y
work_keys_str_mv AT groschannesophie neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT rinnenthaljanleo neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT ronnefarthmaria neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT luxsilke neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT scheelmichael neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT endresmatthias neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT brandtalexanderu neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT paulfriedemann neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT schmitzhubschtanja neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT minneropmartina neurochemicaldifferencesinspinocerebellarataxiatype14and1
AT dosssarah neurochemicaldifferencesinspinocerebellarataxiatype14and1